GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (ASX:TYP) » Definitions » Inventories, Raw Materials & Components

Tryptamine Therapeutics (ASX:TYP) Inventories, Raw Materials & Components : A$0.00 Mil (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Tryptamine Therapeutics Inventories, Raw Materials & Components?

Tryptamine Therapeutics's inventories, raw materials & components for the quarter that ended in Dec. 2024 was A$0.00 Mil.


Tryptamine Therapeutics Inventories, Raw Materials & Components Historical Data

The historical data trend for Tryptamine Therapeutics's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tryptamine Therapeutics Inventories, Raw Materials & Components Chart

Tryptamine Therapeutics Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Inventories, Raw Materials & Components
Get a 7-Day Free Trial - - - - -

Tryptamine Therapeutics Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Dec24
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Tryptamine Therapeutics Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


Tryptamine Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
C/o Bio101 Financial Advisory Pty Ltd, 697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124
Tryptamine Therapeutics Ltd is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. The programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. Its product pipeline includes TRP-8803 (IV-infused psilocin) and TRP-8802 (oral psilocybin).

Tryptamine Therapeutics Headlines

No Headlines